Bluejay Diagnostics (BJDX) Net Cash Flow (2020 - 2026)

Bluejay Diagnostics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 24.84% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at $742089.0 (up 63.12% YoY), while the FY2025 annual figure was $862930.0, down 58.78% from the prior year.
• Net Cash Flow came in at -$1.5 million for Q1 2026 at Bluejay Diagnostics, down from $2.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $5.4 million in Q2 2024 to a low of -$3.3 million in Q1 2023.
• A 5-year average of -$893980.1 and a median of -$1.5 million in 2026 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 420.98% in 2024 and fell as far as 9711.14% in 2024.
• Bluejay Diagnostics' Net Cash Flow stood at -$3.2 million in 2022, then climbed by 9.87% to -$2.9 million in 2023, then surged by 49.32% to -$1.5 million in 2024, then soared by 255.2% to $2.3 million in 2025, then slumped by 165.61% to -$1.5 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$1.5 million, $2.3 million, and -$1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison